It is primarily set up to develop and commercialize non-invasive, protein-based diagnostic applications.
First diagnostic applications in development are based on the proprietary bladder cancer biomarkers and detection antibodies discovered and developed in A*STAR’s Institute of Molecular and Cell Biology (IMCB) by BioCheetah’s Scientific Founder (Prof. Jean Paul Thiery) and the co-Founder/Chief Executive Officer (Dr. Kian-Chung Lee).Read More
An algorithm has been created to enable a more accurate and conclusive testing result
Promising clinical trials aims to detect bladder cancer via a quick liquid biopsy test
Bladder cancer is the 10th most common form of cancer worldwide in both genders and…Read More
BioCheetah clinched two awards at the Asian Entrepreneurship Awards 2019
The Asian Entrepreneurship Award (AEA) 2019 was held from October 30 to November 1 in…Read More